Integer (NYSE:ITGR - Get Free Report)'s stock had its "hold" rating reissued by research analysts at Benchmark in a research report issued to clients and investors on Friday,Benzinga reports.
Several other analysts have also issued reports on ITGR. Citigroup lowered Integer from a "buy" rating to a "neutral" rating in a report on Thursday. Wells Fargo & Company reiterated an "equal weight" rating on shares of Integer in a research note on Friday. Truist Financial reduced their target price on shares of Integer from $137.00 to $121.00 and set a "buy" rating for the company in a report on Wednesday, October 15th. Weiss Ratings reiterated a "hold (c)" rating on shares of Integer in a research report on Wednesday, October 8th. Finally, Raymond James Financial decreased their price objective on shares of Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a research report on Friday, July 25th. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, Integer currently has an average rating of "Hold" and an average price target of $135.57.
Get Our Latest Research Report on Integer
Integer Stock Performance
Shares of NYSE ITGR opened at $73.37 on Friday. Integer has a 12-month low of $66.50 and a 12-month high of $146.36. The firm has a market capitalization of $2.57 billion, a price-to-earnings ratio of 32.32, a price-to-earnings-growth ratio of 0.86 and a beta of 0.97. The company has a current ratio of 3.41, a quick ratio of 2.18 and a debt-to-equity ratio of 0.72. The firm has a 50 day moving average of $104.29 and a 200 day moving average of $112.67.
Integer (NYSE:ITGR - Get Free Report) last issued its quarterly earnings results on Thursday, October 23rd. The medical equipment provider reported $1.79 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.11. Integer had a net margin of 4.61% and a return on equity of 12.27%. The business had revenue of $467.69 million for the quarter, compared to analysts' expectations of $466.45 million. During the same quarter last year, the company posted $1.43 EPS. The company's revenue was up 8.4% compared to the same quarter last year. Integer has set its FY 2025 guidance at 6.290-6.430 EPS. On average, research analysts anticipate that Integer will post 6.01 earnings per share for the current year.
Hedge Funds Weigh In On Integer
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Tributary Capital Management LLC grew its stake in Integer by 92.6% during the third quarter. Tributary Capital Management LLC now owns 499,776 shares of the medical equipment provider's stock valued at $51,642,000 after acquiring an additional 240,226 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Integer by 127.3% in the 3rd quarter. SG Americas Securities LLC now owns 45,951 shares of the medical equipment provider's stock worth $4,748,000 after buying an additional 25,732 shares in the last quarter. KLP Kapitalforvaltning AS increased its holdings in shares of Integer by 7.1% in the 3rd quarter. KLP Kapitalforvaltning AS now owns 7,500 shares of the medical equipment provider's stock worth $775,000 after buying an additional 500 shares during the last quarter. Cerity Partners LLC increased its stake in Integer by 344.2% during the third quarter. Cerity Partners LLC now owns 118,468 shares of the medical equipment provider's stock worth $12,241,000 after acquiring an additional 91,797 shares during the last quarter. Finally, North Growth Management Ltd. raised its position in Integer by 5.1% during the third quarter. North Growth Management Ltd. now owns 103,000 shares of the medical equipment provider's stock valued at $10,593,000 after purchasing an additional 5,000 shares during the period. Institutional investors own 99.29% of the company's stock.
Integer Company Profile
(
Get Free Report)
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Integer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integer wasn't on the list.
While Integer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.